RhumbLine Advisers
AVEO

RhumbLine Advisers’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

RhumbLine Advisers’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,004
Closed -$146K – 3214
2021
Q1 		$146K Buy
20,004
+73
+0.4% +$630 ﹤0.01% 2892
2020
Q4 		$115K Buy
19,931
+6,388
+47% +$36.6K ﹤0.01% 2953
2020
Q3 		$80K Buy
13,543
+215
+2% +$1.06K ﹤0.01% 2910
2020
Q2 		$69K Buy
+13,328
New +$84.1K ﹤0.01% 3007
2019
Q2 		– Sell
-13,837
Closed -$113K – 3046
2019
Q1 		$113K Buy
13,837
+10
+0.1% +$103 ﹤0.01% 2845
2018
Q4 		$221K Buy
13,827
+4,631
+50% +$102K ﹤0.01% 2686
2018
Q3 		$304K Sell
9,196
-68
-0.7% -$1.75K ﹤0.01% 2510
2018
Q2 		$209K Buy
+9,264
New +$220K ﹤0.01% 2715
2014
Q2 		– Sell
-7,011
Closed -$105K – 3097
2014
Q1 		$105K Sell
7,011
-253
-3% -$4.54K ﹤0.01% 2917
2013
Q4 		$134K Sell
7,264
-460
-6% -$9.21K ﹤0.01% 2927
2013
Q3 		$160K Sell
7,724
-47
-0.6% -$1.08K ﹤0.01% 2855
2013
Q2 		$194K Buy
+7,771
New +$332K ﹤0.01% 3001

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RhumbLine Advisers's AVEO Position: Q2 2021 in Review

RhumbLine Advisers sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 20,004 shares — an estimated $146K sold.

RhumbLine Advisers first reported a position in AVEO in Q2 2013 and held it in 12 quarters. The position peaked at $304K in Q3 2018. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

  • RhumbLine Advisers reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 20,004 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $146K.
  • RhumbLine Advisers first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
  • RhumbLine Advisers's AVEO Pharmaceuticals, Inc. position peaked at $304K in Q3 2018.
  • 63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.